SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-20-282616
Filing Date
2020-10-30
Accepted
2020-10-30 16:25:51
Documents
2
Group Members
VERSANT VANTAGE I GP, L.P.VERSANT VANTAGE I GP-GP, LLCVERSANT VANTAGE I, L.P.VERSANT VENTURES VI GP, L.P.VERSANT VENTURES VI GP-GP, LLC

Document Format Files

Seq Description Document Type Size
1 SC 13D d98591dsc13d.htm SC 13D 126731
2 EX-99.1 d98591dex991.htm EX-99.1 7710
  Complete submission text file 0001193125-20-282616.txt   136188
Mailing Address ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104
Business Address ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104 (415) 801-8100
Versant Venture Capital VI, L.P. (Filed by) CIK: 0001687880 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D

Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Subject) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91770 | Film No.: 201277676
SIC: 2836 Biological Products, (No Diagnostic Substances)